image

Pipeline Overview

Innovative Drugs Designed to Improve Patients’ Lives

Our pipeline includes internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies, solid tumors, autoimmune diseases, and viral diseases. It comprises both Chimeric Targeting Molecules (CTMs) for targeted protein degradation to eliminate disease causing proteins and Ligase Inhibitors that target key control elements in immune regulation. Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of CTMs against a set of unique targets.

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryLead OptimizationPreclinicalPhase 1Phase 2Phase 3
Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio
NX-2127 BTK + IMiD Activity (Oral) B-cell malignancies

 

NX-5948 BTK (Oral) B-cell malignancies and autoimmune disease

 

KINASE-CTM3 Undisclosed T-cell malignancies and autoimmune disease

 

COVID-CTMs 3 targets Anti-viral

 

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryLead OptimizationPreclinicalPhase 1Phase 2Phase 3
Ligase Inhibitor Portfolio
NX-1607 CBL-B (Oral) Immuno-oncology

 

DeTIL-0255 CBL-B (ex vivo) Tumor infiltrating lymphocytes

 

LIGASE-INH2 Undisclosed Immuno-oncology

 

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryLead OptimizationPreclinicalPhase 1Phase 2Phase 3
Partners and Subsidiaries
DeCART CBL-B and others (ex vivo) Chimeric antigen receptor T‑cells (CAR-T)

 

Gilead Sciences 5 targets Undisclosed

Undisclosed Progress

 

Sanofi 5 targets Undisclosed

Undisclosed Progress

 

Candidate / TargetPhase
Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio
NX-2127
BTK + IMiD Activity (Oral)
Phase 1
NX-5948
BTK (Oral)
Preclinical
KINASE-CTM3
Undisclosed
Lead Optimization
COVID-CTMs
3 targets
Discovery
Ligase Inhibitor Portfolio
NX-1607
CBL-B (Oral)
Phase 1
DeTIL-0255
CBL-B (ex vivo)
Preclinical
LIGASE-INH2
Undisclosed
Lead Optimization
Partners and Subsidiaries
DeCART
CBL-B and others (ex vivo)
Lead Optimization
Gilead Sciences
5 targets
Undisclosed Progress
Sanofi
5 targets
Undisclosed Progress